Author:
Al Shboul Sofian,El-Sadoni Mohammed,Alhesa Ahmad,Abu Shahin Nisreen,Abuquteish Dua,Abu Al Karsaneh Ola,Alsharaiah Elham,Ismail Mohammad A.,Tyutyunyk-Massey Liliya,Alotaibi Moureq R.,Neely Victoria,Harada Hisashi,Saleh Tareq
Abstract
AbstractNeoadjuvant chemotherapy (NAC) is a frequently utilized approach to treat locally advanced breast cancer, but, unfortunately, a subset of tumors fails to undergo complete pathological response. Apoptosis and therapy-induced senescence (TIS) are both cell stress mechanisms but their exact role in mediating the pathological response to NAC is not fully elucidated. We investigated the change in expression of PAMIP1, the gene encoding for the pro-apoptotic protein, NOXA, following NAC in two breast cancer gene datasets, and the change in NOXA protein expression in response to NAC in 55 matched patient samples (pre- and post-NAC). PAMIP1 expression significantly declined in post-NAC in the two sets, and in our cohort, 75% of the samples exhibited a downregulation in NOXA post-NAC. Matched samples that showed a decline in NOXA post-NAC were examined for TIS based on a signature of downregulated expression of Lamin-B1 and Ki-67 and increased p16INK4a, and the majority exhibited a decrease in Lamin B1 (66%) and Ki-67 (80%), and increased p16INK4a (49%). Since our cohort consisted of patients that did not develop complete pathological response, such findings have clinical implications on the role of TIS and NOXA downregulation in mediating suboptimal responses to the currently established NAC.
Funder
The Hashemite University
Deanship of Scientific Research, University of Jordan
King Saud University
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Siegel, R. L. et al. Cancer statistics, 2023. CA Cancer J. Clin. 73(1), 17–48 (2023).
2. Nounou, M. I. et al. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 9(Suppl 2), 17–34 (2015).
3. Visvanathan, K. et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 31(23), 2942–2962 (2013).
4. Korde, L. A. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J. Clin. Oncol. 39(13), 1485–1505 (2021).
5. Pennisi, A. et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer (Auckl) 10, 103–106 (2016).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献